Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930336 | 0.78 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10PPARGPPARA | |
| SCHEMBL9513770 | 0.76 | BACE1 (0.56) | KDM4EALDH1A1HSD17B10PTGDR2ESR2 | |
| SCHEMBL3194219 | 0.75 | BACE1 (0.54) | ESR2ALOX5ESR1PELI1BACE1 | |
| SCHEMBL4037713 | 0.75 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10PPARGPPARA | |
| SCHEMBL17853796 | 0.74 | PTGDR2 (0.41) | KDM4EALDH1A1HSD17B10PTGDR2ESR2 | |
| SCHEMBL18845273 | 0.72 | GAA (0.39) | KDM4EALDH1A1HSD17B10PTGDR2ESR2 | |
| SCHEMBL4037829 | 0.72 | PTGDR2 (0.45) | PPARGPPARACYP2C9CYP2C19PPARD | |
| SCHEMBL9857403 | 0.72 | ESR2 (0.56) | ALDH1A1HSD17B10PTGDR2ESR2ALOX5 | |
| SCHEMBL29111497 | 0.71 | PTGDR2 (0.49) | KDM4EALDH1A1PTGDR2ESR2ALOX5 | |
| SCHEMBL767483 | 0.71 | ESR1 (0.55) | ALDH1A1HSD17B10PTGDR2ESR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825222-B2 | 2-(4-(2-(2-BIPHENYL-YL-5-METHYL-THIAZOL-4-YL)-ALKOXY)-PHENOXY) -2-METHYL-PROPIONIC ACID DERIVATIVES; ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040019090-A1 | 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents | ELI LILLY & COMPANY | 2004-01-29 | — | — | US | disclosed |
| EP-1206457-B1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6610696-B2 | Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides) | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY & COMPANY LILY CORPORATE CENTER (US) | 2003-03-06 | — | — | US | disclosed |
| WO-2001016120-A9 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | LILLY CO ELI (US) | 2002-07-11 | — | — | WO | disclosed |
| US-6417212-B1 | PHENYLOXAZOLE SUBSTITUTED ON BENZENEOXYPROPIONIC ACID OR ESTERS | ELI LILLY & COMPANY | 2002-07-09 | — | — | US | disclosed |
| EP-1206457-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001016120-A1 | BIARYL-OXA(THIA)ZOLE DERIVATIVES AND THEIR USE AS PPARS MODULATORS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019090-A1 | 2-(4-(2-(2-biphenyl-yl-5-methyl-thiazol-4-yl)-alkoxy)-phenoxy) -2-methyl-propionic acid derivatives; antidiabetic agents | SLC5A2, SLC5A1, GLP1R | KDM4E 3004/4885ALDH1A1 617/4885HSD17B10 469/4885 |
| US-20030045558-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, PPARA, PPARD | KDM4E 4160/4885ALDH1A1 940/4885HSD17B10 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.